about
Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cellsDC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanomaRole of immune-regulatory cells in skin pathology.Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice.Targeting the tumor microenvironment to enhance antitumor immune responsesDissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.Tolerance-inducing strategies in islet transplantationEx vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapyImmunotherapy for melanoma: current status and perspectives.Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature.Immunomodulatory cytokines as therapeutic agents for melanomaUrokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppressionImmunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring.Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Immunotherapy for metastatic melanoma.Microenvironment and tumor progression of melanoma: new therapeutic prospectives.Newer developments in the immunotherapy of malignant melanoma.WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi/IL-21 in a mouse model.Overall survival and PD-L1 expression in metastasized malignant melanoma.Melanoma exosomes enable tumor tolerance in lymph nodes.A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma.Melanoma exosome induction of endothelial cell GM-CSF in pre-metastatic lymph nodes may result in different M1 and M2 macrophage mediated angiogenic processes.Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes.IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competenceMelanoma exosomes promote mixed M1 and M2 macrophage polarization.Macrophages in skin melanoma-the key element in melanomagenesis.Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site
P2860
Q33775637-8A946D63-2801-416F-994D-A5982B06B86AQ34353266-EDAF17B0-5107-4ABA-88B8-376200E4EC82Q34417553-0304DF1C-4BB3-4FC1-B1F6-39D35C81C03AQ34962993-9135B2D7-E6A6-43CE-B98E-2970EEB5E2D4Q35176307-63139BD1-908C-409C-BB3F-B9D73DE342D9Q35832390-1ECDED57-5FE3-4EE2-AEE4-9D3E5DF477A9Q36004707-AE04E3D2-7B7F-428B-807F-22C245D94A4EQ36107158-D78A63C4-E9DA-498C-9071-F7B007435E2CQ36453216-012B5F21-2CFD-4DFA-B540-059CC1E6DE32Q36738000-A213DC91-BB67-4678-9683-F0491011ECE3Q37070203-EBD7C3FC-BC9D-4A86-AC8A-7A7F74BBE24AQ37187551-AB114A42-BCC0-4977-BB39-67AE73322F5DQ37253328-121A38A2-01AB-4327-8EAB-45637C707DD2Q37290632-7F223E2C-34A3-47F7-8C10-AB0D9E15C6E8Q37297526-BD822763-EA56-48E3-9E1C-0E22628407FEQ37801939-235F40E0-751C-4FFF-BBA0-F50F358555CFQ37946772-BFA66249-E974-459E-BFA4-FC695A25A18FQ38049368-545B8F19-FCF8-49E5-A75A-84F35640A5F3Q38084132-0F4D6679-3287-46CF-9DEC-A93A520AE2D3Q39001226-86C39557-C052-414E-AD67-20B515B3B956Q39151226-0741618C-10A8-499A-A6F2-5A2F5793EC2CQ39756798-405D5811-0AF3-4AB4-8F1A-FE165B81314AQ40112908-474D7D59-C700-49D2-836F-3777A84D6E94Q41338809-FA078088-8DD1-4602-9BB2-A6E339742884Q41713128-1BA3CB4E-0984-48C0-9229-482F54656928Q41970314-9546B04A-C339-4E63-A842-79F41A90BCF1Q42698829-7AA28424-BD8F-4FC4-A0A0-C8C44F493C84Q49833213-4B2B49FE-1C8E-46BA-9B26-9147208C5392Q52351121-8BE1CB69-72C9-4734-9421-B3C923CFED6EQ58768316-FE08C886-AA5C-4561-805E-F6983857B227
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune modulation by melanoma-derived factors.
@en
Immune modulation by melanoma-derived factors.
@nl
type
label
Immune modulation by melanoma-derived factors.
@en
Immune modulation by melanoma-derived factors.
@nl
prefLabel
Immune modulation by melanoma-derived factors.
@en
Immune modulation by melanoma-derived factors.
@nl
P2860
P1476
Immune modulation by melanoma-derived factors.
@en
P2093
Dan Ilkovitch
Diana M Lopez
P2860
P304
P356
10.1111/J.1600-0625.2008.00779.X
P577
2008-07-17T00:00:00Z